Glioblastomas may develop de novo or through progression from low-grade or anaplastic astrocytomas. The term 'primary glioblastoma' refers to a glioblastoma that lacks a precursor lesion and has a clinical history of less than three months. On the other hand, the term 'secondary glioblastoma' indicates that the glioblastoma has progressed from a low-grade tumor after a long latency period and often manifests in younger patients. These subtypes of glioblastoma develop via different genetic pathways, and they differ in prognosis and response to therapy. Thus, differential diagnosis of these subtypes and prediction of the factors that affect the progression from low-grade diffuse astrocytoma to secondary glioblastoma would be clinically very important. We present a rare case of secondary glioblastoma, which developed only three months after the follow up imaging evaluations, with a history of low grade glioma, and present the factors that cause rapid progression. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
Glioblastomas may develop de novo or through progression from low-grade or anaplastic astrocytomas. Primary glioblastomas present as full-blown tumors, with rapid development of clinical symptoms, without clinical, radiological, or histopathological evidence of a less-malignant precursor lesion (1) . On the other hand, secondary glioblastomas develop slowly through progression from low-grade diffuse astrocytoma or anaplastic astrocytoma. The mean time for progression from low-grade astrocytoma to secondary glioblastoma was 55 months in a study of secondary glioblastoma (2) . Differential diagnosis of these subtypes of glioblastomas is important to therapeutic approaches. The ability to predict the pace of progression from low-grade diffuse astrocytoma to secondary glioblastoma would be clinically very important. Previous studies reported that the factors that cause shortening of the time of progression from low-grade glioma to glioblastoma were events such as TP53 protein mutation, IDH1 gene mutation, and hypoxia (3, 4) . However, to the best of our knowledge, there are no radiological case reports of correlation with these factors that shorten the time of progression to secondary gliojksronline.org blastoma. We present a rare case of secondary glioblastoma which developed only three months after the initial detection of gliomatosis cerebri and discuss the factors that cause rapid progression.
CASE REPORT
An 80-year-old male presented with syncope and scalp bleeding he had a history of myocardial infarction, which was treated 7 years ago with coronary angiography and stent insertion, and he has been taking aspirin for cardiovascular disease. His vital signs were stable and there were no abnormal laboratory findings. He complained of symptoms of memory loss at the time of syncope. To identify any traumatic injury or brain lesions, contrast-enhanced multi-detector computed tomography images were obtained with a 32 channel dual source CT scanner (SOMATOM Definition; Siemens Medical Solutions, Forchheim, Germany) and magnetic resonance images (MRI) were obtained with 3T; MRI scanner (MAGNETOM Skyra 3T, Siemens Medical Systems, Erlangen, Germany).
On the CT scan, wide regional, patchy and decreased attenuation lesions involving the left insula, the left subinsula, the left hippocampus, the left anterior temporal lobe, left parahippocampus, and some of the left frontal and high parietal cortices and white matter were detected along with mild gyral effacement. On MRI, these wide, regional and patchy lesions showed high signal intensity (SI) on T2-weighted images (WI) and fluid attenuation inversion recovery (FLAIR) images ( Fig. 1A, B ) and slightly increased SI on diffusion weighted imaging and apparent diffusion coefficient maps. On contrast-enhanced T1WI images, these lesions showed decreased SI without an enhancing lesion (Fig. 1C, D) . On perfusion MRI, the cerebral blood volume (CBV) parameter map did not show increased signal at the level of high SI detected on conventional images ( Fig. 1E , F).
The spectroscopic findings showed an increased choline peak and a markedly decreased N-acetylaspartate (NAA) peak in the diffuse ill-demarcated patchy lesion involving the left anterior parahippocampal temporal area ( Fig. 1G ). Diffuse hypoattenuating lesion on CT and bilateral poorly defined areas of high T2SI represent tumor spread and lack of enhancement indicates a preserved blood-brain barrier. This lesion involved three lobes of the brain with preservation of the underlying structures. Increased choline/NAA peak in the tumor as compared with normal brain tissue, supposedly caused by a decrease in NAA, reflects replacement of neurons by neoplastic glial cells. It is consistent with a neoplastic lesion and characteristic findings of WHO grade II glioma. Thus, we suggested that this lesion was gliomatosis cerebri or a multicentric low-grade glioma.
Other noticeable imaging findings were mild chronic ischemic change in the left border zonal frontoparietal white matter area. On CT angiography, total occlusion of the left proximal portion of the middle cerebral artery was detected ( Fig. 2A ).
However, collaterals to the distal run-off were seen faintly. On We decided to perform conservative treatment without biopsy, and during the follow-up, the patient did not present any other symptoms and there was no change in imaging evaluations.
After three months, our patient visited the emergency department with a complaint of right hemiparesis and fine motor disturbance which had started five days ago. On laboratory examinations, there were no abnormal findings. There were no interval changes in the left anterior temporal, insular, and subinsular areas, which showed a diffuse regional hypodense lesion without enhancement on contrast-enhanced CT and high SI on T2WI. Cerebral blood volume parameter map shows an increased signal at the level of high signal intensity detected on conventional MRI. G. On MR spectroscopy, an increased choline peak and a markedly decreased N-acetylaspartate peak are seen in the diffuse ill-demarcated patchy high FLAIR signal intensity, poorly enhancing lesions involving the left anterior parahippocampal temporal area, suggesting gliomatosis cerebri. 4B ). On immunohistochemical staining, positive reaction to GFAP was detected, which indicates the presence of neoplastic cells (Fig. 4C ). Immunohistochemical staining of epithelial membrane antigen and synaptophysin showed negative reactivity. Ki67, a marker of cell division and an indicator of the tumor cell proliferation activity, showed high levels, indicating an increased grade of glioma (Fig. 4D ). p53 expression, which is considered an early event in glioma progression and is generally associated with secondary glioblastoma, rather than primary glioblastoma, showed moderately positive reactivity (Fig. 4E ).
Hypoxia-inducible factor 1a (HIF-1α) is a transcriptional factor that activates tumor survival under an unstable hypoxic tumor microenvironment. Some of the tumor cells showed nuclear staining, indicating that the tumor is in a hypoxic environment 
DISCUSSION
Glioblastoma is the most common brain tumor. Since the terms 'primary and secondary glioblastomas' were first used in 1940 (5), these subtypes have been considered as distinct disease entities that affect different age groups of patients and develop through distinct genetic pathways.
The vast majority of glioblastomas (~90%) which develop rapidly de novo without clinical or histologic evidence of a less malignant precursor lesion were termed as primary glioblastomas (6) . Secondary glioblastomas progress from low-grade diffuse astrocytoma or anaplastic astrocytoma and constitute a relatively rare disease when compared with primary glioblastomas.
At a population level, it was found that only 5% of all cases were secondary glioblastomas with histopathological evidence of a precursor low-grade or anaplastic astrocytoma (1) . MRI. Because of the rapid growth rate, sequential neuroimaging that includes early lesions is rarely carried out (7) . On the other hand, secondary glioblastomas have a lesser degree of necrosis, and are preferentially located in the frontal lobe (6) .
The distinction between primary and secondary glioblasto-
Histologically, primary and secondary glioblastomas are largely indistinguishable. The main reason for this is that both glioblastoma types share similar morphologic features (5) . But even with these indistinguishable histological features, primary and secondary glioblastomas differ in their genetic and epigenetic profiles. Epidermal growth factor receptor overexpression and phosphatase and tensin homolog mutations prevail in primary glioblastomas but are rare in secondary glioblastomas (1) .
TP53 mutations, which are the first genetic alterations identified in astrocytic brain tumors, are rare in primary glioblastomas (< 10%) and have a high incidence (> 65%) in secondary glioblastomas (3) . The incidence of TP53 protein accumulation is significantly higher in secondary glioblastomas (> 90%) than in primary glioblastomas (< 35%) (8) . IDH1 mutations, indicating that these tumors are derived from neural precursor cells that differ from those of primary glioblastomas, were first reported in many patients with secondary glioblastomas and were associated with good prognosis (9) . It is now agreed that IDH1 mutation is a definitive diagnostic molecular marker of secondary glioblastomas and more reliable and objective than clinical and /or pathologic criteria.
Unlike the characteristics of the subtypes of glioblastomas mentioned above, our case shows a rapidly growing secondary glioblastoma with internal necrotic portions. We suggest that the causes of a rapid growth rate and necrosis in our case are genetic characteristics and previous ischemic injury detected on CT angiography and TFCA as total occlusion of the left middle cerebral artery. The time of progression to anaplastic astrocytoma or glioblastoma is somewhat shorter for low-grade astrocyto-mas carrying a TP53 mutation (3). This result is in accordance with our case as a high level of p53 expression was observed on immunohistochemical staining. Secondary glioblastomas lacking IDH1 mutations have a shorter clinical history. In a previous study, patients with glioblastomas lacking IDH1 mutations had a mean duration of preceding clinical symptoms of 3.9 months, which was significantly shorter than that in patients with IDH1 mutant glioblastoma (mean, 15.2 months) (4) . It is suggested that the absence of extensive necrosis and peritumoral brain swelling in secondary glioblastoma is due to the slow growth rate (5) . However, our case showed central necrosis and peritumoral brain swelling which occurred within three months.
In a study for determining the morphologic features of glioblastoma that link vascular pathology and hypoxia, hypoxia-mediated activation of the coagulation system was presented as the cause of intravascular thrombosis, which aggravates intratumoral hypoxia, and this leads to abnormal endothelial cell proliferation and tumor necrosis (10) . Intratumoral necrosis is the hallmark of glioblastoma and it is due to rapid cell proliferation and inadequate vascularization leading to insufficient oxygen supply to the tumor. Chronic exposure to low levels of oxygen has been linked to several phenotypic changes, and it frequently produces necrotic zones and induces changes in the proteome of tumor cells that lead to impaired growth or cell death and elaborate microvascular proliferation that heralds a phase of more malignant progression. Hypoxia-inducible factor 1 (HIF-1) is one of the major regulators of tumor cell adaptation to hypoxic stress, lead to the establishment of a vicious circle of hypoxia and malignant progression (10) . This can be applied to our case with the findings of CT angiography and sequelae of the previous hypoxic ischemic change detected on conventional MRI and perfusion MRI.
Differential diagnosis of these subtypes of glioblastomas is important to therapeutic approaches. The ability to predict the pace of progression from low-grade diffuse astrocytoma to secondary glioblastoma would be clinically very important. Based on the genetic profiles and previous ischemic injury detected on neuroimaging, rapid progression of secondary glioblastoma can be predicted and it can affect patient prognosis.
